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Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have been traditionally 
considered as indistinctly slowly progressing conditions; recent evidence proves that a subset of cases 
have a rapid evolution, so that MPNs’ prognosis needs to be personalized.   
We identified a new morphological parameter, defined as Megakaryocytic Activation (M-ACT) 
based on the coexistence of megakaryocytic emperipolesis, megakaryocytes (MK) clusters formation 
and evidence of arrangement of collagen fibers around the perimeter of MK. We retrospectively 
analyzed the bone marrow biopsy of two MPNs cohorts of patients with polycythemia (PV) (n=64) 
and non-PV patients [including essential thrombocythemia (ET), and early/prefibrotic primary 
myelofibrosis (PMF)] (n=222). 
 M-ACT showed a significant correlation with splenomegaly, white blood cell (WBC) count, 
and LDH serum levels in both groups, with JAK2 V617F allele burden in PV patients, and with CALR 
mutations, and platelet count in non-PV patients. Progression-free survival, defined as PV-to-secondary 
MF progression and non-PV-to-overt PMF, was worse in both PV and early/prefibrotic PMF patients 
with M-ACT in comparison to those without M-ACT (P<.0001). Interestingly, M-ACT was not found 
in the subgroup of ET patients. 
In conclusion, M-ACT can be helpful in the differential diagnosis of MPNs and can represent a 








Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) represent a group of 
hematological disorders that originate from the neoplastic transformation of a pluripotent stem cell and 
are characterized by clonal proliferation of one or more hematopoietic progenitors in the bone marrow 
(BM) and in extramedullary sites. 
According to the WHO 2017 classification, MPNs can be divided into three main sets: 
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), whose 
early stages’ differential diagnosis is often challenging.1 
While MPNs have been traditionally considered as indistinct slow progressing conditions,2,3 
recent evidence, on the contrary, demonstrated that a subset of cases had a rapid evolution, leading 
different groups to develop several prognostic scores, mainly based on clinical and laboratory 
parameters with less emphasis on morphological, immunophenotypic and molecular data.4 
The first prognostic score was The International Prognostic Scoring System (IPSS), edited in 2009 by 
an international study group, which enabled survival estimation at the time of diagnosis primarily 
employing five clinical and hematologic parameters;5 this model was further revised as Dynamic 
International Prognostic Scoring System (DIPSS) and then as DIPSS-plus score.6,7 The above, 
nonetheless, applied to already-established myelofibrosis (both PMF and post-PV/ET MF) only, 
determining survival from the time of disease progression/transformation to death without considering 
the heterogeneous disease history before the appearance of BM changes.8   
On the basis of advances in MPNs’ molecular profiling, in order to improve the prognostic 
prediction in PMF patients, novel models included JAK2, CALR, and MPL mutation status in addition 
to the IPSS parameters.8 Moreover, novel insights were provided by in-depth analysis of genomic 
subsets with different clinical outcomes.9 Recent publications have introduced new risk models for 
PMF, namely MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age 
patients),10 MIPSS70+ version 2.0 (karyotype-enhanced MIPSS70) and GIPSS (genetically-inspired 
prognostic scoring system).11,12 Similar risk models have been recently introduced for both ET and PV 
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under the name of MIPSS-ET and MIPSS-PV, highlighting the prognostic contribution of spliceosome 
gene mutations.13 However, all these predictive models did not consider morphological and 
phenotypical features, except bone marrow (BM) fibrosis grade in the MIPPS70 model. 
In this study we evaluated a new morphological parameter, defined by the coexistence of  
emperipolesis of megakaryocytes (MK) (i.e. the presence of an intact cell within the cytoplasm of 
another cell), MK clustering and peri-MK fibrosis in bone marrow (BM) biopsy, which was named 
Megakaryocytic Activation (M-ACT). Larocca et al. in 2015 demonstrated that extensive BM 
emperipolesis associated to BM fibrosis was present in patients affected by gray platelet syndrome, with 
up to 65% MK containing 2-4 leukocytes engulfed within the cytoplasm;14  a similar phenomenon has 
been described either in BM patients with PMF,15 and in the BM of animal models of myelofibrosis.16,17 
We demonstrated that M-ACT is a useful morphological parameter in forecasting both PV and 
early/prefibrotic PMF to myelofibrosis progression and could also help in the differential diagnosis 





Patients' features  
Formalin-fixed, paraffin-embedded BM biopsy specimens, obtained from the posterior superior 
iliac spine,19 were available in our Institute of Pathology for 460 patients clinically diagnosed with a 
MPN  and followed at our Institute of Hematology (Fondazione Policlinico Universitario “A. Gemelli”, 
IRCCS) from January 2005 to October 2019. The study was carried out in accordance with the 
Declaration of Helsinki and the consent for retrospective analysis of all clinical data, according to the 
Ethical Committee of the Catholic University School of Medicine, and obtained by all the patients at 
the hospital admission. Patients were clinically followed-up over the observation time by one single 
team physician (V.D.S. and E.R as senior members). 
All 286 cases were sorted out up until October 2019, according to three inclusion criteria: 
clinical diagnosis of either PV or non-PV MPN, first BM biopsy at diagnosis for non-PV cohort and 
within 0-24 months from the clinical diagnosis for PV cohort and no grade 2-3 bone marrow fibrosis. 
Accordingly, patients with diagnosis of overt PMF or secondary myelofibrosis were excluded. 
Furthermore, BM biopsies were revised by two skilled pathologists (L.M.R. and M.M.) and categorized 
according to the WHO 2017 criteria (PV, ET, early/prefibrotic PMF).  
Clinical and hematological data (according to WHO 2017 criteria) were collected in order to 
trace LDH increase (i.e. LDH serum levels ≥  250 UI/L), palpable splenomegaly, leukocytosis (i.e. 
WBC ≥ 11 × 109/L), high hemoglobin level (i.e. Hgb > 16 g/dL for woman and Hgb > 16.5 g/dL for 
man) and thrombocytosis (i.e. PLT ≥ 450 × 109/L) for each patient at diagnosis. We also verified the 
occurrence of Arterial/Venous (A/V) thrombotic events and/or major bleeding events during the 
clinical course (until October 2019) for each case. Thrombotic and bleeding events were defined as 
previously described.20 JAK2 V617F mutation and allele burden analysis, CALR exon 9 mutations and 
MPL exon 10 mutations were performed as previously described.20 Progression to secondary 
myelofibrosis was defined from the patient chart review and based on the International Working 
Group for Myelofibrosis Research and Treatment (IWG-MRT) consensus criteria.21 
6 
 
The main clinical, hematological and molecular characteristics of the 286 patients are shown in 
Table 1 for PV cohort (64 patients), in Table 2 and Table 1S for non-PV cohort [including 199 
early/prefibrotic PMF patients (Table 2) and 23 ET patients (Table 1S)].  
 
Bone marrow biopsy analysis and M-ACT histological parameters 
 All the biopsy specimens had a suitable length (at least 1.5-2 cm) in order to obtain at least ten 
partially preserved intertrabecular areas, since subcortical medullary lacunae are less cellular than deep 
ones (especially in the elderly) and since focal pathologies can have a deep localization.22 After 
collection, each biopsy specimen was kept in a properly-labelled clean container filled with 10% natural 
buffered formalin at pH 7.6 for 12 hours for fixation, decalcified with a Decalcifier II solution (Leica 
Biosystems, Milan, Italy) for 1 hour at room temperature, then fixed with 10% natural buffered 
formalin at pH 7.6 for 2 hours and finally included in paraffin. Sections, 3-5 μm thick, were taken from 
each block for staining with H&E and Gordon&Sweet’s silver staining to evaluate morphological 
features and fibrosis.23,24 The specimens were concurrently examined and reviewed by two pathologists 
experienced in BM biopsy interpretation (L.M.L. and M.M.), who were blinded toward the patients’ 
characteristics and survival. Cases with disagreement were discussed using a multiheaded microscope 
until agreement was achieved. The agreement indices (Cohen’s K) between the two pathologists were 
very good: k=0.83 and k=0.85 for PV group and for non-PVs group, respectively. 
 In the definition of M-ACT the following parameters were examined in detail (as shown in 
Figure 1): (1) MK emperipolesis, (2) MK clustering and (3) peri-MK fibrosis.  
1) MK emperipolesis was defined as the presence of one or more leukocyte or a precursor of 
hematopoiesis within the cytoplasm of at least 30% MKs in the specimen.  
2) MK clustering was defined as an aggregation of 3 or more megakaryocytes in close contact 
with each other and at least 25% of MKs are distributed in clusters in the specimen. 
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3) peri-MK fibrosis was used to define the arrangement of collagen fibers around the 
perimeter of the vast majority of MKs, underlining their primary role in the genesis of 
fibrosis.  
M-ACT positive patients showed the contemporary presence of all three parameters and M-
ACT was evaluated only on the first BM biopsy at diagnosis and before any treatment.  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad-Prism 5 software (Graph Pad Software, San 
Diego, CA) and MedCalc version 10.2.0.0 (MedCalc Software, Mariakerke, Belgium).25 Statistical 
comparison of continuous variables was performed by the Mann-Whitney U-test (t test), as appropriate. 
Comparison of categorical variables was performed by chi-square statistic, using the Fisher’s exact test. 
To evaluate the agreement between the two pathologists about the presence or absence of M-ACT in 
bone marrow biopsies, we calculated the inter-rater agreement (Kappa) using MedCalc software. 
The endpoint was progression-free survival (PFS), defined as the time between the first 
diagnosis and PV-to-secondary MF progression and early/prefibrotic PMF -to-overt PMF progression, 
respectively. 
We followed the WHO 2017 criteria to establish the progression for PV-to-secondary MF and 
for early/prefibrotic PMF to overt myelofibrosis progression.1 
Kaplan-Meier survival curves were plotted and differences in survival between groups of 
patients were compared using the log-rank test. Multivariate analysis was performed using the Cox 
proportional hazards regression analysis including only those clinical and biological variables with a p-







Megakaryocytic activation in PV cohort 
Twenty-six out of the 64 PVs did not meet histological criteria for M-ACT (40%), versus 38 
who did (60%). In PV cohort, M-ACT showed a significant correlation with one clinical parameter, i.e. 
palpable splenomegaly (P=.001), and with hematologic parameters, like platelet count (P=.0001), LDH 
serum levels (P=.002) and WBC count (P=.001). On the other hand, no significant correlation was 
found between M-ACT and age (P=1.00), gender (P=1.00), A/V thrombosis (P=.43), while major 
bleeding (P=.06), Hgb level (P=.06) and JAK2V617F burden>50% (P=.059) showed a certain 
associative trend (Table 1).  
We found that patients with M-ACT had a significant lower progression-free survival (PFS) 
than those without M-ACT (Table 1; Figure 2 panel A, for PFS: median PFS for M-ACT positive 
patients 58 months versus median PFS for M-ACT negative patients 108 months, P<.0001, HR 6.81, 
95% CI from 3.48 to13.32). Moreover, JAK2V617Fallele burden≥50% and history of major bleeding 
had a significant correlation with a worse PFS (P=.0225 and P=.0174, respectively, Figure S1), while 
WBC count>11x109/l showed a certain trend toward significance (P=.0823, Figure S1). Conversely, age 
(P=.3718), gender (P=.3645), LDH serum level (P=.1305), PLT count (P=.5643), Hgb level (P=.1024) 
and A/V thrombosis (P=.4216) did not show significant correlation with PFS. 
Multivariate analysis of PFS, including M-ACT status, JAK2 status, WBC count and history of 
major bleeding, showed that the presence of M-ACT and the JAK2V617Fallele burden were the only 
significant predictors (for M-ACT status, P<.0001, HR 10.4180, 95% CI: from 4.0978 to 26.4858; for 
JAK2V617Fallele burden≥50%, P=.0105, HR 0.0105, 95% CI: from 1.2855 to 6.6460; Table 3).  
 
Megakaryocytic activation in non-PV MPNs cohort 
One hundred and nine of 199 early/prefibrotic PMF patients did not meet histological criteria 
for M-ACT (55%), versus 90 who did (45%). In this cohort, M-ACT showed a strong correlation with 
clinical parameters, such as palpable splenomegaly (P=.001) and history of major bleeding (P=.001), 
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and with hematologic parameters, like platelet count (P=.0001), LDH serum levels (P=.003), WBC 
count (P=.002), presence of CALR mutations (P=.001; Table 2). Notably, we found a significant 
association between M-ACT and CALR type 1 mutation (P=.0001) while we did not find a significant 
correlation between M-ACT and CALR type 2 mutation (P=1.0). We found a significant yet milder 
correlation with gender, being M-ACT more prevalent in females (P=.05), and with JAK2V617F allele 
burden≥50% (P=.04). On the contrary, no significant correlation was found between M-ACT and age 
(P=1.00), Hgb level (P=.43), MPL mutations (P=1.00) and A/V thrombosis (P=.42; Table 1).  
Similarly to what happened in the PV cohort, when we correlated M-ACT status with PFS, we 
found that patients with early/prefibrotic PMF and with M-ACT had a significant lower PFS than 
those without M-ACT (Table 1; Figure 2 panel B, for PFS: median PFS for M-ACT positive patients 44 
months versus median PFS for M-ACT negative patients 77 months, P<.0001, HR 3.17, 95% CI from 
2.27 to 4.44).  Moreover, male gender, CALR type 1 mutations, WBC count>11x109/l, presence of 
palpable splenomegaly, PLT≥600x109/l and LDH≥250 U/l had a significant correlation with a worse 
PFS (P=.0187, P<.0001, P<.0001, P<.0001, P<.0001 and P=.0025, respectively, Figure 2S). 
Conversely, age (P=.8831), major bleeding (P=.7244), JAK2 V617F allele burden≥50% (P=.3459), Hgb 
level (P=.5234), MPL mutations (P=.2268) and A/V thrombosis (P=.2003) did not show significant 
correlation with PFS. 
Multivariate analysis of PFS, including M-ACT status, CALR status, WBC count, gender, LDH 
serous level, splenomegaly, and platelet count, showed that the presence of M-ACT and CALR type 1 
mutation, WBC count>11x109/l  and male gender were the significant predictors (for M-ACT status, 
P<.0001, HR 2.1510, 95% CI: from 1.5598 to 2.9661; for CALR status, P=.0285, HR 1.446, 95% CI: 
from 1.0395 to 2.0124; for WBC count, P=.0211, HR 1.5425,95% CI: from 1.0673 to 2.2294; for 
gender, P=.0074, HR 1.5024, 95% CI: from 1.1153 to 2.0240; Table 4).  
In the non-PV MPNs cohort, we also analyzed a small subgroup of 23 ET patients. We did not 
find M-ACT in any of the ET BM biopsies performed at the time of the diagnosis. The ET patients 
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had a better PFS in comparison to patients with early/prefibrotic PMF either with M-ACT (Figure 3S; 
P<.0001) and without M-ACT (Figure 3S; P<.0001). 
Interestingly, we found that the incidence of M-ACT among triple-negative patients in the non-
PV cohort was significantly lower in respect to patients with a driver gene mutation [21 out of 85 
(24.7%) triple negative patients vs 90 out of 222 (40.5%); P=.0115], and that triple-negative patients 
with M-ACT also had a significant lower PFS than those without M-ACT (median PFS for M-ACT 
positive triple-negative patients 56 months versus median PFS for M-ACT negative triple-negative 






For about two decades, one of the most important problems in the treatment of patients with 
MPNs has been the identification of biological and non-biological factors that could represent a 
determinant key to the prediction of prognosis. Accordingly, several prognostic scores have succeeded 
over time, mainly based on clinical, hematological and molecular parameters, in order to identify the 
fraction of MPNs patients that could have a high risk of developing a leukemic transformation or a 
bone marrow fibrotic failure. However, none of these models take the morphological parameters into 
factual consideration, while these parameters play an important role in the diagnostic phase.  
In this retrospective and monocentric study, we propose a novel morphological parameter, 
defined as M-ACT, as a new possible predictive marker of fibrotic evolution among Philadelphia-
negative MPNs. Furthermore, this new parameter seems to be useful to supplement WHO 2017 
classification criteria in the differential diagnosis of the MPN subtype between ET and early/prefibrotic 
PMF. 
In our study, carried out on a large cohort of MPNs’ bone marrow biopsies at diagnosis, 
extensive evidences support this statement. In fact, in univariate analysis M-ACT correlates with 
relevant MPN clinical and hematologic parameters (see Table 1 and 2), such as palpable splenomegaly, 
WBC or PLT count, and LDH levels, but also with molecular profiles defined by the JAK2 V617F 
allele burden and CALR mutations (especially the CALR type 1 mutation).  
In PV patients the PFS was influenced at the multivariate analysis by the JAK2 V617F allele 
burden > 50%, as already reported;26 in early/prefibrotic PMF patients’ PFS was influenced by the 
presence of the CALR type 1 mutation, WBC count>11x109/l and male gender, in agreement with 
previous reports.27 
Moreover, patients with M-ACT had a significant correlation with a worse PFS and with an 
overt-myelofibrotic bone marrow failure, in both PVs and early/prefibrotic PMF (P<.0001). This last 
result is also confirmed at multivariate analysis. Interestingly, PV and early/prefibrotic PMF patients 
with this parameter showed a rapid clinical progression before the end of the 5-year follow-up, 
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suggesting that M-ACT could be an early predictive marker capable of precociously identifying patients 
that need a closer follow-up.  
Numerous scientific papers have highlighted that in the evolution towards myelofibrosis of 
MPNs, a central role seems to be played by megakaryocytes. Patients with MPNs and fibrotic evolution 
showed a significant increased number of megakaryocytes with an abnormal nuclear/cytoplasmic ratio 
and a reduced polyploid state, often organized in clusters.27,28 Experiments using in-vitro cultures of 
CD34+ hematopoietic stem cells of patients with fibrotic MPNs have shown that megakaryocytes 
expand excessively, are immature and show delayed apoptosis owing to increased expression of the 
anti-apoptotic factor Bcl-xL.29 Moreover, mice with a megakaryocyte-specific deficiency of the 
transcription factor–encoding gene GATA1 show elevated numbers of immature megakaryocytes in 
the bone marrow and an increased and pathologic neutrophil emperipolesis that may represent one of 
the mechanisms leading to myelofibrosis by releasing fibrogenic MK cytokines and neutrophil 
proteases in the microenvironment of in-vivo experiments.14,16 Finally, megakaryocytes from individuals 
with PMF secrete increased levels of the fibrotic cytokines such as TGF-β, compared to 
megakaryocytes from healthy individuals, and the extracellular matrix (ECM) microenvironment, 
especially the fibronectin component, is able to sustain progenitor cell proliferation and 
megakaryopoiesis in a TPO-independent manner.16,30,31 These pro-fibrotic cytokines would presumably 
act mainly in the microenvironment near to those megakaryocyte clusters which are, in turn, their main 
producers. Furthermore, the criteria defining the megakaryocytic activation could represent the 
morphological counterpart of what is postulated by in-vitro and in-vivo studies regarding the role of 
megakaryocytes in the bone marrow fibrotic evolution of patients with MPNs.  
Recent evidence has suggested that treating patients with early-stage MF may lead to better 
outcomes with a less severe splenomegaly, a lower incidence of cytopenia, and less-severe bone marrow 
fibrosis. However, the argument is debated, especially considerating the adverse events of the JAK2 
inhibitor treatment (ruxolitinib). M-ACT parameter, as an early predictive marker capable of 
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precociously identifying patients with an overt-myelofibrotic bone marrow failure, could also select 
those patients that would benefit from precocious treatment.32  
Our analysis not only supports the role of the megakaryocytes and its activation in the evolution 
of PV and early/prefibrotic PMF, but also seems to suggest that, for the treatment of this neoplasia, as 
well as the inhibition of specific mutations, which may partially alter the natural history of the disease, 
the blockage of the fibrotic evolution and therefore of its main key-player, the megakaryocyte, should 
be a future therapeutic strategy to be investigated.30 
M-ACT is also a very useful morphological parameter in the diagnostic phase of MPNs. In fact, 
none of the ET patients showed M-ACT, which when present, identifies only an early/prefibrotic 
PMF.  
Interestingly the M-ACT showed a significant lower incidence in triple-negative patients in 
comparison to those with a driver gene mutation (24.7% vs 40.5%) reinforcing the idea of a more 
indolent disease for this subgroup though maintaining its predictive role for the fibrotic evolution also  
in triple-negative patients. 
In addition, M-ACT parameter evaluation represents an easily executable analysis with a high 
agreement index between pathologists. Moreover, the search for M-ACT on the bone marrow biopsies 
in the diagnostic phase of MPN patients can be performed widely without the need for further analysis 
such as immunohistochemistry or molecular analysis. 
The main limitation of our study is the retrospective design, so that the estimate of the time of 
progression to overt myelofibrosis and the estimate of PFS based on the patient chart review can lack 
of accuracy.  Moreover, the team physician was unchanged over years and the criteria for diagnosing 
progression to overt myelofibrosis were aligned with those of the IWG-MRT consensus.21 
Although we analyzed a large cohort, the results of this monocentric study need confirmation in 
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Table 1. Correlation between M-ACT and the main PV patient’s clinical and molecular features.  
 
 
JAK2-RT: JAK2 V617F allele burden; Hgb: Hemoglobin, serum levels; LDH: Lactate dehydrogenase, serum 
levels; WBC: White blood cell count; PLT: Platelet count; A/V: Arterial/venous; HR: Hazard ratio; CI: 
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1.01 [0.791 – 
1.059] 
1.00 










78.3 (26-116) 95.5 (72-116) 44.7 (26-48) 2.78 [0.036-
2.589] 
.0001 
















36 (56.2%) 16 (25.0%) 20 (31.3%) 1.83 [0.179-
3.795] 
.001 












A/V thrombosis 24 (37.5%) 8 (12.5%) 16 (25.0%) 1.02 [0.882 – 
1.069] 
.43 






Table 2. Correlation between M-ACT and the main early/prefibrotic PMF patient’s clinical 
and molecular features. 
 






HR [CI 95%] 
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JAK2-RT > 50% 37 (18.6%) 26 (13.1%) 11 (5.5%) 1.27 [0.073-2.879] .04 
CALR mut. 60 (30.1%) 19 (9.5%) 41 (20.6%) 2.14 [0.301-1.902] .001 
CALR type 1 
CALR type 2 
46 (23.1%) 









MPL mut. 3 (1.5%) 2 (1.0%) 1 (0.5%) 1.00 [0.663-1.044]  1.00 
Time-progression2 67.3 (15-
109) 





15.2 (13.6-16.4) 1.04 [0.923-1.088] .43 




407.9 (288-612) 1.54 [0.045-3.235] .003 
Palpable splenomegaly 111 (55.8%) 49 (24.6%) 62 (31.1%) 1.82 [0.1797-3.759] .001 
WBC5 11.8 (7.5-
18.7) 





710.3 (490-861) 2.46 [0.087-2.279] .0001 
A/V thrombosis 74 (37.2%) 30 (15.1%) 44 (22.1%) 1.03 [0.243-1.912] .001 
Major bleeding 30 (15.1%) 14 (7.0%) 16 (8.0%) 1.00 [0.928-1.079] .42 
 
JAK2-RT: JAK2 V617F allele burden; CALR mut: CALR exon 9 mutations (type 1 + type 2); MPL mut: MPL exon 10 
mutations; Hgb: Hemoglobin: serum levels; LDH: Lactate dehydrogenase, serum levels; WBC: White blood cell count; PLT: 
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Table 3. PV cohort: PFS multivariate analysis. 
 
Covariate b SE Wald P Exp(b) 95% CI of Exp(b) 
Major bleeding 
 -0.1562 0.3890 0.1614 0.6879 0.8554 0.3991 to 1.8333 
JAK2 status 1.0726 0.4191 6.5500 0.0105 2.9229 1.2855 to 6.6460 
M-ACT 2.3435 0.4761 24.2335 
 <0.0001 10.4180 4.0978 to 26.4858 
WBC 
 -0.1520 0.3604 0.1780 0.6731 0.8590 0.4239 to 1.7407 
 
b= coefficient estimates; SE=standard error for coefficient estimates b; Exp(b)= Hazard Ratio value; 95% CI of 
Exp(b)= 95% confidence interval of Hazard Ratio. Major bleeding vs no major bleeding; JAK2 burden≥50% vs 
JAK2 burden<50% (JAK2 status); Megakaryocyte activation vs no megakaryocyte activation (M-ACT); 



































Table 4. Early/prefibrotic PMF subset: PFS multivariate analysis. 
 
Covariate b SE Wald P Exp(b) 95% CI of Exp(b) 
WBC 0.4334 0.1879 5.3207 0.0211 1.5425 1.0673 to 2.2294 
M-ACT 0.7659 0.1640 21.8235 
 <0.0001 2.1510 1.5598 to 2.9661 
CALR status 0.3690 0.1685 4.7956 0.0285 1.4463 1.0395 to 2.0124 
Gender 0.4071 0.1520 7.1702 0.0074 1.5024 1.1153 to 2.0240 
LDH 0.1831 0.1749 1.0958 0.2952 1.2009 0.8524 to 1.6919 
Palpable splenomegaly 0.3084 0.1746 3.1217 0.0773 1.3613 0.9668 to 1.9167 
PLT 0.2415 0.1638 2.1729 0.1405 1.2731 0.9235 to 1.7551 
 
b= coefficient estimates; SE=standard error for coefficient estimates b; Exp(b)= Hazard Ratio value; 95% CI of 
Exp(b)= 95% confidence interval of Hazard Ratio. CALR mutations vs no CARL wt (CALR); Gender male vs 
Gender female (Gender); Megakaryocyte activation vs no megakaryocyte activation (M-ACT); WBC≥11.0x109/l 
vs WBC<11.0x109/l; LDH≥250 UI/l vs LDH<250 UI/l; Palpable splenomegaly vs no palpable splenomegaly; 





























Figure 1. Representative images of Megakaryocytic activation (M-ACT) in PV (panels A-C) and in 
early/prefibrotic PMF (panels D-F). Panels A and D: the panels show the emperipolesis, defined as the 
presence of at least one leukocyte (indicated by black arrows) or a precursor of hematopoiesis within 
the cytoplasm of a MK (400X magnification). Panels B and E: the panels show MK clustering, defined 
as an aggregation of 3 or more megakaryocytes in close contact with each other (200X and 400X 
magnification for panel B and E, respectively). Panels C and F: the panels show the peri-MK fibrosis, 
defined as the arrangement of collagen fibers around the perimeter of activated MKs (400X and 200X 
magnification for panel C and F, respectively). 
Figure 2. Kaplan-Meier curves for PFS of PV and of early/prefibrotic PMF patients. Panel A shows 
the Kaplan-Meier curve for PFS of PV patients stratified by M-ACT. Panel B shows the Kaplan-Meier 
curve for PFS of early/prefibrotic PMF patients by M-ACT. M-ACT positive patients (red-line) was 







ET Overall (n=23) 





JAK2-RT > 50% 7(30.4%) 
CALR mut. 2 (8.7%) 
CALR type 1 
CALR type 2 
1 (4.3%) 
1 (4.3%) 
MPL mut. 0 (0%) 
Hgb3 14.3 (13.8-15.7) 
LDH serum levels4 245.1 (180-322) 
Palpable splenomegaly 4 (17.4%) 
WBC5 9.8(7.1-11.8) 
PLT6 615.3 (453-811) 
A/V thrombosis 6 (26.1%) 
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Supplementary figure legend 
Figure 1S 
Kaplan-Meier curves for PFS of PV patients stratified for JAK2 status, bleeding and WBC count. 
Patients with JAK2 burden≥50% and history of bleeding (red line) had a significant correlation with a 
worse PFS (for JAK2 status, P=.0225, HR 2.1274, 95% CI from 1.1124 to 4.0683; for bleeding, 
P=.0174, HR 2.9615, 95% CI from 1.2104 to 7.2458) respect to those with JAK2 burden<50% and 
without history of bleeding (blu-line). Patients with WBC count≥11x109/l (red line) showed a certain 
trend toward significance with a worse PFS (P=.0823; HR 0.5171, 95% CI from 0.2458 to 1.0880) 
respect to those with WBC count<11x109/l (red line).  
Figure 2S 
Kaplan-Meier curves for early/prefibrotic PMF stratified for CALR mutations (type 1 and type 2 
mutation), PLT count, WBC count, splenomegaly, LDH level and gender. Patients with WBC 
count≥11x109/l, CALR type 1 mutation,  PLT≥450x109/l, palpable splenomegaly, LDH≥250UI/l and 
female gender (red line) had a significant correlation with a worse PFS (for WBC count, P<.0001, HR 
1.9458, 95% CI from 1.4395 to 2.6303; for PLT count, P<.0001, HR 1.9993, 95% CI from 1.4597 to 
2.7384; for splenomegaly, P<.0001, HR 1.8993, 95% CI from 1.4132 to 2.5524; for LDH level, 
P=.0025, HR 1.5678, 95% CI from 1.1710 to 2.0991; for gender, P=.0187, HR 1.4125, 95% CI from 
1.0592 to 1.8835; for CALR status; CALR type 1 mutation versus CALR wild type, P<.0001, HR 
2.1476, 95% CI from 1.4040 to 3.2850) respect to those with WBC count<11x109/l, CALR wild-type,  
PLT<450x109/l, absence of palpable splenomegaly, LDH<250UI/l and male gender (blu-line).  
Figure 3S 
Kaplan-Meier curves for PFS early/prefibrotic PMF and ET stratified for M-ACT parameter. ET 
patients that did not have a M-ACT in any case showed a significant correlation with a better PFS in 
comparison to both early/prefibrotic PMF with that without M-ACT (P<.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
